Anns Mahboob

Sep 12, 2024 | mdpi.com | Anns Mahboob |Hasan Ali |Mahmoud Yousef |AlJazi AlNaimi

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jul 26, 2024 | preprints.org | Anns Mahboob |Hasan Ali |Mahmoud Yousef |Mlaak Rob

PreprintReviewVersion 1This version is not peer-reviewedVersion 1: Received: 25 July 2024 / Approved: 26 July 2024 / Online: 26 July 2024 (13:28:14 CEST)Mahboob, A.; Ali, H. O.; Al Naimi, A. J.; Yousef, M.; Rob, M.; Al-Muhannadi, N. A.; Senevirathne, D. K. L.; Chaari, A. Immunotherapy For PD and AD: A Promising Disease Modifying Therapy. Preprints 2024, 2024072156. https://doi.org/10.20944/preprints202407.2156.v1Mahboob, A.; Ali, H. O.; Al Naimi, A. J.; Yousef, M.; Rob, M.; Al-Muhannadi, N.

May 25, 2023 | mdpi.com | Kevin Zhai |Pradipta Paul |Anns Mahboob |Alexandra Kammen

1. IntroductionAlzheimer’s disease (AD) is a neurodegenerative disorder that affects millions of people worldwide, particularly the elderly. According to a WHO report in 2019, approximately 50 million people worldwide suffer from AD, with an incidence rate for dementia of 712 cases per 100,000 people globally in 2016 [1].